摘要
目的对比研究SOX方案与奥沙利铂联合卡培他滨对晚期胃癌患者血清微小RNA(miR)-34a及let-7i含量的影响。方法选取144例晚期胃癌患者,随机分为对照组和观察组,各72例。对照组给予奥沙利铂+卡培他滨,观察组给予替吉奥胶囊+奥沙利铂(SOX方案),21 d为1个周期,两组患者均持续随访至治疗后1年。评价两组患者临床疗效。于治疗前及治疗6个周期,采用酶联免疫吸附试验测定患者血清中肿瘤标志物:糖类抗原(CA)19-9、CA125、癌胚抗原(CEA)水平;采用实时荧光定量PCR法测定患者血清中miR-34a和let-7i相对表达水平。统计患者化疗期间发生的0~Ⅳ度不良反应。结果观察组客观缓解率和疾病控制率均显著高于对照组(P<0.05)。治疗前,两组血清肿瘤标志物CA19-9、CA125和CEA水平组间比较差异不具有统计学意义(P>0.05);治疗6个周期后,两组血清肿瘤标志物CA19-9、CA125和CEA水平均显著降低,且观察组显著低于对照组(P<0.05)。治疗前,对照组和观察组血清miR-34a和let-7i表达差异无统计学意义(P>0.05);治疗6个周期后,两组血清miR-34a和let-7i表达水平均显著增加,且观察组显著高于对照组(P<0.05)。对照组和观察组化疗过程中毒副反应主要为Ⅰ~Ⅳ度,且对照组仅手足综合征发生率显著高于观察组(P<0.05);其他毒副反应的发生率组间比较差异均不具有统计学意义(P>0.05)。观察组中位PFS显著长于对照组(P<0.001)。结论SOX方案与奥沙利铂联合卡培他滨相比,可以显著提高晚期胃癌患者临床治疗效果,降低患者血清肿瘤标志物水平,提高血清miR-34a和let-7i表达水平。
Objective To compare the effects of SOX regimen and oxaliplatin combined with capecitabine on serum microRNA(miR)-34a and let-7i contents in patients with advanced gastric cancer.Methods A total of 144 patients with advanced gastric cancer were selected and randomly divided into control group and observation group,with 72 cases in each group.Control group were given ox-aliplatin+capecitabine,and the observation group were given Tiggio capsules+oxaliplatin(SOX regimen)for a period of 21 d.Pa-tients in both groups were followed up for one year after treatment to evaluate the clinical efficacy of the two groups of patients.Before treatment and 6 cycles of treatment,the enzyme-linked immunosorbent assay was used to determine the tumor markers in the patient's serum:carbohydrate antigen(CA)19-9,CA125,carcidoembnoolc antigex(CEA)levels.The relative expression levels of miR-34a and let-7i in serum were determined by real-time fluorescent quantitative PCR.Adverse reactions of 0~Ⅳdegree during chemotherapy were analyzed.Results The objective response rate and disease control rate of observation group were significantly higher than those in control group(P<0.05).Before treatment,there was no statistically significant difference in serum tumor markers CA19-9,CA125 and CEA levels between the control group and the observation group(P>0.05);after 6 cycles of treatment,the serum tumor markers CA19-9,CA125 and CEA levels of the two groups were significantly reduced,and those in the observation group were significantly low-er than those in the control group(P<0.05).Before treatment,there was no statistically significant difference in serum miR-34a and let-7i expressions between the control group and the observation group(P>0.05);after 6 cycles of treatment,the serum miR-34 and let-7i expression levels of the two groups were significantly increased,and those in the observation group were significantly higher than those in the control group(P<0.05).Toxic side effects during chemotherapy in the control group and observation group were mainly gradeⅠ~Ⅳ,and the incidence of hand-foot syndrome in the control group was significantly higher than that in the observation group(P<0.05);there was no statistically significant difference in the incidence of other toxic side effects between groups(P>0.05).The median PFS of the study group was significantly longer than that in the control group(P<0.001).Conclusions Compared with oxali-platin combined with capecitabine,the SOX regimen could significantly improve the clinical treatment effect of patients with advanced gastric cancer,reduce the levels of serum tumor markers,and increase the levels of serum miR-34a and let-7i expression.
作者
唐炜
郝吉庆
胡楠
张燕
崔方博
高尔云
TANG Wei;HAO Ji-Qing;HU Nan(Department of Oncology,the First Affiliated Hospital of Anhui Medical University,Hefei 243000,Anhui,China)
出处
《中国老年学杂志》
CAS
北大核心
2023年第20期4903-4907,共5页
Chinese Journal of Gerontology
基金
国家自然科学基金资助项目(No.81802347)。
